Prevenar13

BIOLOGICAL11 trials

Conditions

AtherosclerosisCoughFebrile IllnessHIV/AIDSHerpes ZosterIgG DeficiencyImmunizationInfluenza

Phase 1

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

CompletedNCT04830358

EuBiologics Co.,LtdPneumococcal Disease

Start: 2020-05-28End: 2021-02-01Updated: 2021-10-07

Phase 2

PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency

CompletedNCT01847781

Karolinska University HospitalIgG Deficiency

Start: 2013-05-31End: 2013-12-31Updated: 2014-06-16

Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

CompletedNCT03439657

GlaxoSmithKlineHerpes Zoster

Start: 2018-04-12End: 2020-03-03Updated: 2022-01-11

Phase 4

Pneumococcal Vaccines Early and in Combination

CompletedNCT01174849

Menzies School of Health ResearchOtitis Media

Start: 2011-08-31End: 2018-03-15Updated: 2018-10-18

Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life

CompletedNCT01735084

Menzies School of Health ResearchCough, Febrile Illness, Lower Respiratory Tract Infection +2

Start: 2013-03-12End: 2019-10-03Updated: 2020-03-25

Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients

CompletedNCT01781871

Helsinki University Central HospitalKidney Transplantation, Liver Transplantation

Start: 2013-01-31End: 2017-10-04Updated: 2017-10-05

PCV13 + Hepatitis a Vaccine for Adults

CompletedNCT01926860

Helsinki University Central HospitalMeasurement of Immune Response to Hepatitis a, Measurement of Immune Response to Prevenar13

Start: 2013-08-24End: 2020-04-28Updated: 2024-12-05

Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years

CompletedNCT02215863

Korea University Guro HospitalInfluenza, Streptococcus Pneumoniae

Start: 2014-09-30End: 2015-03-31Updated: 2015-04-01

Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants

WithdrawnNCT02918708

Public Health EnglandImmunization, Vaccination

Updated: 2019-08-28

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults

CompletedNCT03838497

Korea University Guro HospitalHIV/AIDS, Streptococcal Pneumonia

Start: 2015-04-02End: 2017-02-28Updated: 2019-02-12

Unknown Phase

Pneumococcal vaccine against atherosclerosis

Active, not recruitingNL-OMON21732

N.A.Atherosclerosis

Start: 2016-04-04Target: 24Updated: 2024-02-28

PLoS Medicine2024-06-034 citations

Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.

2024-02-287 citations

Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.

2022-06-2710 citations

The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.

2021-12-2512 citations

08. Concomitant Administration of the Adjuvanted Recombinant Zoster Vaccine (RZV) with 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Is Safe and Does Not Interfere with Immunogenicity of Either Vaccine in Adults Aged ≥ 50 Years

Open Forum Infectious Diseases2021-11-01

Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.

2021-03-089 citations

10-Valent pneumococcal non-typeable <i>H. influenzae</i> protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial

BMJ Open2020-05-017 citations

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea.

2017-12-257 citations

The Pneumocell-study: Vaccination of IgG1- and IgG2-deficient patients with Prevnar13.

2017-04-112 citations

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.

2016-12-0321 citations

Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial

BMJ Open2015-01-0127 citations